News
Coming soon
This is Margin of Safety, a brand new site by George O'Toole that's just getting started. Things will be up and running here shortly, but you can subscribe in the meantime if you'd like to stay up to date and receive emails when new
Ramsdens Holdings
Ramsdens has issued a notably strong trading update, upgrading expectations for FY26 profit before tax to more than £21mn, ahead of prior market forecasts of £18.6mn and up from £16.2mn in FY25. That is a substantial step-up, particularly this early in the year. The shares rose around 9
Grainger
At a time when UK property shares are still recovering from higher interest rates and policy uncertainty, Grainger’s latest trading update offers reassurance. Rents are rising steadily, homes remain largely full, and new developments continue to be delivered into a market where rental demand still exceeds supply. Against a
Company Analysis
Shares in Ramsdens Holdings have risen sharply over the past year, alongside a clear improvement in both turnover and profitability. The business appears to be in much better shape than it was, but the key question for investors is whether the shares now offer a good entry point or whether
Company Analysis
SkinBioTherapeutics has not explicitly disclosed a £750k Zenakine royalty figure in its FY25 accounts, with commercial terms remaining confidential. However, the CEO has publicly acknowledged that straightforward arithmetic using figures in the annual report allows this amount to be inferred as attributable to Zenakine royalties. At first glance, a number
Company Analysis
Grainger is a straightforward company by listed property standards. Its value is best understood through the scale of its operations, the shift to REIT status, and the macro backdrop for UK rental housing. The latest full-year results cover the year to September 2025, which margin has reviewed alongside subsequent disclosures.